This report is concerned with the antiviral activity of sodium 5-aminosulfonyl-2,4-dichlorobenzoate, M12325 (Fig. 1) . It includes evaluations of the in vitro activities of M12325 against various RNA and DNA viruses, appraisals of this agent's cytotoxicity, comparison of its activity with that of amantadine in mice infected with various viruses, and appraisals of acute toxicity.
MATERIALS AND METHODS Drugs. M12325 was supplied by Hodogaya Chemical Co., Ltd. (Tokyo, Japan). It was a water-soluble white powder with a melting point of 232 to 233.5°C. M12325 was dissolved in physiological saline solution or distilled water for addition to the culture medium or administration to mice, respectively. 1-Adamantanamine hydrochloride (amantadine; Wako, Tokyo, Japan) was used as the reference drug.
Animals. Female ICR mice, weighing 16 to 18 g, were used for the infection study and for the drug control study. Male ddY mice, weighing 25 to 30 g, were used for the acute toxicity study.
Viruses The minimum inhibitory concentration (MIC) was defined as the lowest mean concentration of the drug that caused complete inhibition of the cytopathic effect of the viruses in six independent experiments.
In the cytotoxicity study, 2 x 104 cells seeded in a microtiter plate were incubated with the drug in 0.2 ml of MEM at 37°C under 5% CO2. MDCK, Vero, and HEL cells were incubated for 48, 72, and 72 h, respectively. After the incubation, cells not stained with 0.1% trypan blue and thus considered to be viable were counted microscopically. The drug concentration that showed 50%o inhibition of cell growth (IC50) was calculated by the probit method in three experiments.
The therapeutic ratio was expressed as a ratio of the IC50 to the MIC.
Anti-INFV-W activity with single administration in mice. Groups of 10 mice were inoculated intranasally with 103"8 TCID50 of INFV-W in 20 ,ul of physiological saline solution containing 0.2% BSA under light ether anesthesia. M12325 was injected orally in single doses of 10, 30, 100, and 300 mg/kg at 1 h after or 1 h before inoculation. The dose of amantadine was 300 mg/kg. Mortality data were recorded for 2 weeks after inoculation.
Antiviral activity with multiple administration in mice. Groups of 10 mice were inoculated intranasally with 103 8 TCID50 of INFV-W, INFV-F, INFV-K, and INFV-G; 103"8 TCID50 of PIV-3 together with 0.1 U of trypsin; and 105 TCID50 of HSV-1, as described above. M12325 was administered orally in multiple doses of 30, 100, and 300 mg/kg twice daily for 14 days starting 1 h before inoculation. The dose of amantadine was 300 mg/kg. Mortality data were recorded for 2 weeks after inoculation.
Virological study for mice. Groups of 10 mice were inoculated intranasally with 103 TCID50 of INFV-W and sacrificed 4 days after inoculation. M12325 was injected intraperitoneally in multiple doses of 10 and 30 mg/kg twice daily for 4 days, starting 1 h after inoculation. Lungs were excised for measurement of lung consolidation and virus titer. Lung consolidation was estimated by the following arbitrary scores: 3, 100 to 75% of the lung; 2, 75 to 50% of the lung; 1, 50 to 25% of the lung; 0, 25 to 0%o of the lung. The virus titer was determined by the cytopathic effect of the virus in a serial 10-fold dilution on MDCK cells and expressed as the TCID50-Drug control. Drug controls were run in parallel with the in vivo experiments. Three groups of 10 mice received via the oral route either distilled water or M12325 in twice daily doses of 300 mg/kg and 1 g/kg for 2 weeks without infection. Mortality data, body weight gain, and clinical signs of abnormalities were recorded.
Oral and intraperitoneal acute toxicity studies in mice. M12325 was administered orally and intraperitoneally to each group of 10 mice. Mortality and clinical signs of abnormalities were observed for 7 days. The 50%o lethal dose (LD50) was calculated by the method of Wilcoxon and Litchfield (9) .
Statistical evaluation of the results. The significance of differences in survival rate was evaluated by the Fisher exact test. The significances of the differences in virus titer and body weight gain were evaluated by Student's t test. The significance of the difference in lung consolidation was evaluated by the rank sum test. respectively. M12325 at concentrations up to 3,160 ,g/ml showed no inhibition of these cell growths, resulting in higher therapeutic ratios, at Anti-INFV-W activity with single administration in mice. Single oral doses of M12325, ranging from 10 to 300 mg/kg, administered 1 h before or 1 h after inoculation, showed doserelated increases in survival rates and a prolongation of mean survival days in INFV-W-infected mice (Table 2) . A single dose of 300 mg/kg of amantadine, administered 1 h before inoculation, showed significant activity, whereas the same dose of amantadine, administered 1 h after challenge, showed only a weak and insignificant activity.
RESULTS
Antiviral activity with multiple administration in mice. Multiple oral doses of M12325, ranging from 30 to 300 mg/kg, showed significant increases in survival rates and a prolongation of mean survival days in mice infected with RNA viruses such as INFV-W, INFV-F, INFV-K, INFV-G, and PIV-3 (Table 3 ). Multiple oral doses of M12325 at 300 mg/kg showed no activity in HSV-1-infected mice. Amantadine at multiple doses of 300 mg/kg showed significant antiviral activity against INFV-F and INFV-K, but insignificant activity against INFV-W, INFV-G, and PIV-3.
Virological study in mice. Multiple doses of 30 mg/kg of M12325 for 4 days after INFV-W inoculation reduced body weight loss, lung weight, the lung consolidation score, and the virus titer (Table 4) . Drug control. Body weight gains (mean standard error) of mice treated with 0, 300, and 1,000 mg/kg of M12325 were 5.10 ± 0.55, 6.10 ± 0.53, and 5.04 ± 0.04 g, respectively. M12325 at multiple doses up to 1,000 mg/kg was neither lethal nor productive of significant behavioral, neurological, or autonomic nervous system abnormalities throughout the experimental period of 14 days.
Acute toxicity in mice. M12325 at single oral PIV-3 and RSV, as well as against DNA viruses. The activity of amantadine against INFV-W was equal to that against INFV-K. This may be related to the finding that the activity of amantadine depends on the assay system (5).
Unlike amantadine, the activity of M12325 was not reduced when this compound was added to the cell culture at 1 h after viral inoculation (Table 1 ). This suggests that M12325 acts mainly on viral replication.
At concentrations up to 3,160 ,ug/ml, M12325 showed no cytotoxic effect against MDCK, Vero, and HEL cells, whereas amantadine showed toxicity against these cells at concentrations of 98 to 127 ,ug/ml. Higher therapeutic ratios of M12325 suggest that the compound may have selective toxicity against RNA viruses.
These findings indicate that M12325, unlike the known antiviral compounds (3, 7, 8) , has a broader spectrum of activity against a wide variation of RNA viruses, possibly with selective toxicity.
The antiviral activity of M12325 was also demonstrated in infected mice. A single administration of M12325, ranging from 10 to 300 mg/kg, 1 h after or 1 h before the INFV-W inoculation, reduced the mortality of mice significantly. However, the activity of amantadine was reduced when administered 1 h after the inoculation. This result may be closely related to the result obtained from in vitro experiments and suggests the difference in action of M12325 and amantadine.
The activity of multiple doses of M12325 was evaluated in mice infected with INFV-W, INFV M12325 was tolerated in multiple oral doses up to 1 g/kg, single oral doses up to 10 g/kg, or single intraperitoneal doses up to 3 g/kg in mice.
